Paxil Linked to Suicide, Birth Defects

December 18, 2013

Important Information

ClassAction.org is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects:
Women taking Paxil who delivered a child with a congenital heart defect, persistent pulmonary hypertension or other birth defect. Also, families of Paxil patients aged 18 to 24 who committed suicide.
Damages:
Pregnant women taking Paxil have a greater risk of delivering children with congenital, cardiovascular or pulmonary malformations. Paxil has also been linked to suicidal tendencies in patients aged 18 to 24.
Company(ies):
Glaxo Smith Kline
Additional Details:
Paxil is an anti-depressant that corrects the brain's chemical imbalance of serotonin. It is prescribed to treat depression and anxiety disorders.
Date:
On Dec. 8, 2005 the FDA released a warning about birth defects associated with Paxil use. A year later, the FDA announced that Paxil must include an expanded warning detailing the possible risk of suicide for patients ages 18 to 24.
Type of Lawsuit:
Mass Tort